MA33339B1 - Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales - Google Patents

Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales

Info

Publication number
MA33339B1
MA33339B1 MA34419A MA34419A MA33339B1 MA 33339 B1 MA33339 B1 MA 33339B1 MA 34419 A MA34419 A MA 34419A MA 34419 A MA34419 A MA 34419A MA 33339 B1 MA33339 B1 MA 33339B1
Authority
MA
Morocco
Prior art keywords
treatment
antibody
tau
brain diseases
phosphorylated
Prior art date
Application number
MA34419A
Other languages
Arabic (ar)
English (en)
Inventor
Bernd Bohrmann
Ulrich Goepfert
Fiona Grueninger
Walter Huber
Hans-Willi Krell
Valeria Lifke
Olaf Mundigl
Sonja Offner
Laurence Ozmen
Michael Schraeml
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33339B1 publication Critical patent/MA33339B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un anticorps se liant à Tau, phosphorylé au niveau de la sérine 422 (pS422), caractérisé en ce qu'il se lie spécifiquement au fragment Tau phosphorylé de SEQ ID n° 9 et à Tau pS422, mais ne se lie pas à Tau ni au fragment MCAK phosphorylé de SEQ ID n° 17, ledit anticorps étant utile dans le traitement d'une tauopathie.
MA34419A 2009-06-10 2010-06-08 Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales MA33339B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09007656 2009-06-10
EP09008487 2009-06-30
PCT/EP2010/003437 WO2010142423A2 (fr) 2009-06-10 2010-06-08 Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales

Publications (1)

Publication Number Publication Date
MA33339B1 true MA33339B1 (fr) 2012-06-01

Family

ID=42753372

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34419A MA33339B1 (fr) 2009-06-10 2010-06-08 Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales

Country Status (23)

Country Link
US (2) US8609097B2 (fr)
EP (1) EP2440578B1 (fr)
JP (2) JP2012529275A (fr)
KR (1) KR101429367B1 (fr)
CN (1) CN102459333B (fr)
AR (1) AR077016A1 (fr)
AU (1) AU2010257799B2 (fr)
BR (1) BRPI1012993A2 (fr)
CA (1) CA2762594C (fr)
CL (1) CL2011003122A1 (fr)
CO (1) CO6450613A2 (fr)
CR (1) CR20110606A (fr)
EC (1) ECSP11011514A (fr)
HK (1) HK1166331A1 (fr)
IL (1) IL216509A0 (fr)
MA (1) MA33339B1 (fr)
MX (1) MX2011012837A (fr)
NZ (1) NZ596187A (fr)
PE (1) PE20120543A1 (fr)
RU (1) RU2536247C2 (fr)
SG (1) SG176754A1 (fr)
TW (1) TW201103560A (fr)
WO (1) WO2010142423A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
CN107488228A (zh) 2008-04-11 2017-12-19 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
US9126931B2 (en) 2009-06-10 2015-09-08 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compound
WO2012023597A1 (fr) 2010-08-20 2012-02-23 中外製薬株式会社 Composition contenant un composé tétracyclique
PL2627672T3 (pl) 2010-10-11 2018-11-30 Biogen International Neuroscience Gmbh Ludzkie przeciwciała anty-tau
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
SG10201703771WA (en) 2011-09-19 2017-06-29 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
SG11201403106SA (en) 2011-12-20 2014-12-30 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
MX354049B (es) * 2011-12-21 2018-02-09 Hoffmann La Roche Método rápido para la clonación y expresión de segmentos génicos de regiones variables de anticuerpos cognados.
KR102133610B1 (ko) 2012-05-31 2020-07-14 고리쓰다이가쿠호진 오사카 시리쓰다이가쿠 인지증 치료제 또는 예방제
AU2013302540B2 (en) 2012-08-16 2018-02-15 Ipierian, Inc. Methods of treating a tauopathy
WO2014030750A1 (fr) 2012-08-24 2014-02-27 中外製薬株式会社 ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
KR20210084688A (ko) 2012-08-24 2021-07-07 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
TR201815994T4 (tr) 2012-09-25 2018-11-21 Chugai Pharmaceutical Co Ltd Ret inhibitörü.
WO2014096321A1 (fr) * 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps spécifiques de la protéine tau phosphorylée à la sérine 422 et leurs utilisations pour traiter et diagnostiquer les tauopathies
ES2816700T3 (es) * 2012-12-21 2021-04-05 Biogen Ma Inc Anticuerpos anti-tau humanos
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP3783017A1 (fr) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Variant de région fc
RS60031B1 (sr) * 2013-12-20 2020-04-30 Hoffmann La Roche Humanizovana anti-tau(ps422) antitela i načini upotrebe
EP2899208A1 (fr) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Anticorps à domaine unique de camélidés dirigés contre des protéines tau phosphorylées et procédés de production de conjugués de ceux-ci
WO2015122922A1 (fr) 2014-02-14 2015-08-20 Ipierian, Inc. Peptides tau, anticorps anti-tau, et leurs procédés d'utilisation
KR102412321B1 (ko) 2014-04-25 2022-06-22 추가이 세이야쿠 가부시키가이샤 4환성 화합물을 고용량 함유하는 제제
CA2946268A1 (fr) 2014-04-25 2015-10-29 Chugai Seiyaku Kabushiki Kaisha Cristal de compose tetracyclique
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI664190B (zh) * 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 ４環性化合物的非晶質體
EP3207057A2 (fr) * 2014-10-16 2017-08-23 F. Hoffmann-La Roche AG Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
SI3221349T1 (sl) * 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
EP3240804A4 (fr) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation
RU2740261C2 (ru) 2015-01-16 2021-01-12 Чугаи Сейяку Кабусики Кайся Комбинированное лекарственное средство
EP3816179A3 (fr) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Variant de région fc comprenant un domaine de liaison fcrn modifié
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
AU2016249406B2 (en) * 2015-04-16 2021-06-10 H. Lundbeck A/S. Use of anti-PACAP antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
SG10201911349YA (en) 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use
AR105089A1 (es) * 2015-06-24 2017-09-06 Hoffmann La Roche ANTICUERPOS ANTI-TAU(pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
UA124616C2 (uk) 2015-07-06 2021-10-20 Юсб Біофарма Срл Зв'язуюче тау-білок антитіло
MX2017015908A (es) * 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EP3334761B1 (fr) * 2015-08-13 2023-07-19 New York University Molécules à base d'anticorps sélectives pour l'épitope {p} ser404 de tau et leurs utilisations dans le diagnostic et le traitement d'une tauopathie
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
US10913783B2 (en) 2016-04-15 2021-02-09 H. Lundbeck A/S Humanized anti-PACAP antibodies and uses thereof
PE20190227A1 (es) 2016-07-12 2019-02-13 H Lundbeck As Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
KR102645073B1 (ko) 2016-12-07 2024-03-11 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
EP3551220A1 (fr) 2016-12-07 2019-10-16 Genentech, Inc. Anticorps anti-tau et leurs méthodes d'utilisation
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
BR112019017021A2 (pt) * 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
TWI809562B (zh) 2017-10-16 2023-07-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
JP2021512602A (ja) * 2018-02-01 2021-05-20 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． タウに特異的に結合する結合分子
TW202020151A (zh) 2018-07-03 2020-06-01 瑞士商赫孚孟拉羅股份公司 用於調制 Tau 表現之寡核苷酸
EP3829634A1 (fr) 2018-07-31 2021-06-09 Eli Lilly and Company Polythérapie
WO2020050241A1 (fr) 2018-09-04 2020-03-12 中外製薬株式会社 Procédé de production de composé tétracyclique
CA3183835A1 (fr) 2020-06-25 2021-12-30 Jeanne E. Baker Anticorps a haute affinite ciblant la proteine tau phosphorylee a la position 413 de serine
WO2023092004A1 (fr) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à tau

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233723T2 (de) 1991-12-06 2009-02-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
AU5508798A (en) 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP1876185A1 (fr) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag Anticorps qui reconnaît les polypeptides phosphorylés

Also Published As

Publication number Publication date
EP2440578B1 (fr) 2017-03-08
TW201103560A (en) 2011-02-01
JP2012529275A (ja) 2012-11-22
CR20110606A (es) 2012-01-12
EP2440578A2 (fr) 2012-04-18
CA2762594C (fr) 2017-02-28
US8609097B2 (en) 2013-12-17
AU2010257799A1 (en) 2011-12-01
CA2762594A1 (fr) 2010-12-16
HK1166331A1 (en) 2012-10-26
PE20120543A1 (es) 2012-05-23
BRPI1012993A2 (pt) 2018-01-16
KR101429367B1 (ko) 2014-08-11
WO2010142423A2 (fr) 2010-12-16
KR20120024952A (ko) 2012-03-14
CO6450613A2 (es) 2012-05-31
WO2010142423A3 (fr) 2011-05-26
AR077016A1 (es) 2011-07-27
MX2011012837A (es) 2011-12-16
CN102459333A (zh) 2012-05-16
CN102459333B (zh) 2015-07-15
CL2011003122A1 (es) 2012-07-20
JP6513617B2 (ja) 2019-05-15
ECSP11011514A (es) 2012-01-31
US20110059093A1 (en) 2011-03-10
SG176754A1 (en) 2012-01-30
RU2536247C2 (ru) 2014-12-20
RU2011152816A (ru) 2013-07-20
JP2017031176A (ja) 2017-02-09
US9290567B2 (en) 2016-03-22
US20130310541A1 (en) 2013-11-21
IL216509A0 (en) 2012-02-29
AU2010257799B2 (en) 2013-10-17
NZ596187A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
MA33339B1 (fr) Utilisation d'un anticorps anti-tau ps422 pour le traitement de maladies cérébrales
NL301089I2 (nl) imlifidase
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
MA31918B1 (fr) Agents et épitopes de liaison à wise
MA45655B1 (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA33825B1 (fr) Analogue du peptide d'oxyntomoduline
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
MA33826B1 (fr) Analogue du peptide d'oxyntomoduline
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
CR11298A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano
NO20061412L (no) Terapi av okulaere foretyrrelser
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
MA30384B1 (fr) Therapies combinatoires
EA201070539A1 (ru) НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
EA200702193A1 (ru) Гликозилирование белков
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
NO20082749L (no) Fremgangsmate for fremstilling av ferri-succinylkasein
MA38161A1 (fr) Anticorps anti-bmp-6